Maniinc recalls dental burs, forecasts strong 2026 growth

Maniinc reported consolidated net sales of JPY29,968 million for the fiscal year ended August 31, 2025, a 5.1% increase year-on-year, while ordinary income decreased by 2.3% to JPY8,271 million. Profit attributable to owners of parent fell by 17.8% to JPY5,167 million, influenced by a voluntary recall of 4.2 million MANI DIA-BURS in China due to registration information issues, resulting in a JPY1,192 million impact on operating income. The company expects to resume sales of these dia-burs by Q2 FY2026.

Looking ahead, Maniinc forecasts a robust performance for the fiscal year ending August 31, 2026, projecting net sales of JPY32,800 million (up 9.4%), ordinary income of JPY8,950 million (up 8.2%), and profit attributable to owners of parent of JPY6,450 million (up 24.8%). This positive outlook is supported by strategic initiatives, including the expansion of the JIZAI series, a strategic partnership with MicroSurgical Technology for ophthalmic knives in the US, and the establishment of a Malaysian sales subsidiary as its Asia regional headquarters.

Maniinc also announced its director candidates for the November 19, 2025, General Meeting, proposing new appointments including Hiroyuki Sasa and Nao Tsuchiya as outside directors, and the reappointment of current directors. The company plans to increase its annual dividend per share from JPY39 for FY2025 to JPY41 for FY2026, reflecting its commitment to stable shareholder returns.